Xueji Biotechnology
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $200M
Overview
A stem cell biotech using iPSC-derived platelets to create off-the-shelf cell therapies for thrombocytopenia and develop related drugs.
HematologyOncologyInfectious DiseaseCritical Care
Technology Platform
Proprietary ex vivo directed differentiation system for induced pluripotent stem cells (iPSCs) to produce functional platelets and platelet lysates at scale.
Opportunities
The global platelet shortage and risks of donor-derived pathogens create a massive market for a safe, scalable, off-the-shelf alternative.
The parallel market for high-quality, xeno-free cell culture supplements (like iHPL) in the booming cell therapy industry provides a near-term revenue stream.
Risk Factors
Technical risks in scaling iPSC differentiation to industrial levels while maintaining platelet function and safety; significant regulatory hurdles for the first-in-class cell therapy; and competition from other biotechs in the stem cell-derived blood product space.
Competitive Landscape
Competes with other stem cell-derived platelet developers like Megakaryon and PlateletBio, and traditional blood banking. Differentiates via its integrated iPSC platform, focus on the Chinese market, and dual therapeutic/research product strategy.